Management of Neurofibromatosis Type 2
Open Access
- 1 February 1999
- journal article
- research article
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 78 (2) , 91-96
- https://doi.org/10.1177/014556139907800207
Abstract
Neurofibromatosis type 2 (NF2), an as-yet incurable disease that predisposes patients to multiple intracranial and spinal tumors, requires a team approach to treatment, because of its multisystem nature. Included on the team should be neuro-otologists, neurosurgeons, ophthalmologists, geneticists, audiologists, speech therapists and other rehabilitative personnel, including counselors, psychologists and, occasionally, psychiatrists. The challenge is to arrive at a treatment strategy that preserves useful hearing and quality of life without increasing the risk of complications to the facial nerve or compromising neurologic status. Choosing the best treatment approach involves considering a complex set of competing factors that affect various aspects of the patient's outcome.Keywords
This publication has 7 references indexed in Scilit:
- Type 2 neurofibromatosis: the need for supraregional care?The Journal of Laryngology & Otology, 1993
- A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.Journal of Medical Genetics, 1992
- Neurofibromatosis 1 (Recklinghausen Disease) and Neurofibromatosis 2 (Bilateral Acoustic Neurofibromatosis)Annals of Internal Medicine, 1990
- Stereotactic Gamma Knife RadiosurgeryArchives of Neurology, 1990
- NeurofibromatosisArchives of Neurology, 1988
- Bilateral Acoustic Tumors: A Diagnostic and Surgical ChallengeJAMA Otolaryngology–Head & Neck Surgery, 1980
- Multiple Cell Origin of Hereditary NeurofibromasNew England Journal of Medicine, 1971